Effects of β-alanine and Sodium Bicarbonate Supplementation on Physical Capacity and Biochemical Markers Concentrations

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexFemale
Age16-40
SponsorPoznan University of Physical Education

About this trial

This randomized, double-blind, placebo-controlled, parallel-group study aims to evaluate the potential synergistic effect of beta-alanine (BA) and sodium bicarbonate (SB) supplementation, compared to their separate administration or placebo (PL), on physical performance and selected blood biochemical markers in highly trained female basketball players.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

written consent to participate,

general good health condition,

a current medical clearance to practice sports,

training experience: at least 4 years,

Disqualifiers

current injury,

any health-related contraindication,

declared general feeling of being unwell,

taking supplements, especially ergogenic supplements that modulate extra- and intracellular capacity 3 months prior to research (except taking protein and/or carbohydrate powders, isotonic drinks),

Trial design

Design model

Parallel

Treatments tested in this trial

  • BA and SB supplementation

    Dietary supplement

    Assigned Interventions: * Beta-alanine (BA) * Sodium bicarbonate (SB) Description: • Participants receive beta-alanine and sodium bicarbonate Intervention list \& supplementation details: 1. Beta-alanine (BA) * Form: Gelatin capsules * Substance: Pure beta-alanine * Daily dose: 6.4 g/day * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner) * Supplementation period: days 1 to 28 2. Sodium bicarbonate (SB) * Form: Gelatin capsules * Substance: Pure sodium bicarbonate * Daily dose: 0.3 g/kg body mass per day * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner) * Supplementation period: days 21 to 28 of BA or PL1 supplementation Rationale: • This group tests the combined effects of BA and SB

  • BA and PL2 supplementation

    Dietary supplement

    Participants in this intervention group will undergo chronic supplementation with beta-alanine (BA) and an inert placebo (PL2) matched to the sodium bicarbonate (SB) protocol. * Beta-alanine (pure, in gelatin capsules) will be administered at a total daily dose of 6.4 g, divided into four servings taken with meals, over a period of 28 consecutive days. * PL2 (placebo matched to SB, in gelatin capsules) will be administered from Day 21 to Day 28 of beta-alanine supplementation, at a daily dose of 0.3 g per kg of body mass, divided into three equal servings taken with meals. This group allows for evaluation of the isolated effects of BA supplementation when combined with a placebo comparator to SB

  • PL1 and SB supplementation

    Dietary supplement

    Assigned Interventions: * Placebo matched to BA (PL1) * Sodium bicarbonate (SB) Description: • Participants receive only sodium bicarbonate as the active compound and placebo capsules matching the BA protocol. Intervention list \& supplementation details: 1. Placebo matched to BA (PL1) * Form: Gelatin capsules * Substance: Inert substance matched in appearance and dosing schedule to BA * Daily dose: 6.4 g/day * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner) * Supplementation period: days 1 to 28 2. Sodium bicarbonate (SB) * Form: Gelatin capsules * Substance: Pure sodium bicarbonate * Daily dose: 0.3 g/kg body mass per day * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner) * Supplementation period: days 21 to 28 of BA or PL1 supplementation Rationale: • This group tests the isolated effects of SB

  • PL1 and PL2 supplementation

    Dietary supplement

    Assigned Interventions: * Placebo matched to BA (PL1) * Placebo matched to SB (PL2) Description: • Participants receive two matched placebos. Intervention list \& supplementation details: 1. Placebo matched to BA (PL1) * Form: Gelatin capsules * Substance: Inert substance matched in appearance and dosing schedule to BA * Daily dose: 6.4 g/day * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner) * Supplementation period: days 1 to 28 2. Placebo matched to SB (PL2) * Form: Gelatin capsules * Substance: Inert substance matched in appearance and timing to SB * Daily dose: 0.3 g/kg body mass per day * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner) * Supplementation period: days 21 to 28 of BA or PL1 supplementation Rationale: • This serves as the control group for comparison with all active intervention arms.

Treatment groups

100 Participants
are divided into 4 treatment groups
Group A: BA and SB supplementation (first group)Experimental treatment 1 intervention
Group B: BA and PL2 supplementation (second group)Experimental treatment 1 intervention
Group C: PL1 and SB supplementation (third group)Experimental treatment 1 intervention
Group D: PL1 and PL2 supplementation (fourth group)Placebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Changes in anaerobic capacity during Wingate Anaerobic Test (WAnT)

Assessment of peak power (PP), average power (AP), minimum power (MP), power drop (PD) \[W (Watts)\] using the Monark 894E ergometer (measured before and after incremental cycling test (ICT)) before and after supplementation (BA - beta-alanine; SB - sodium bicarbonate; PL - placebo; with BA+SB, BA+PL2, PL1+SB, or PL1+PL2).

Time frame
During the first study visit on the first day and during the second study visit after 28 days of intervention.
2

Changes in Countermovement Jump (CMJ) performance

Assessment of three consecutive countermovement jump (CMJ) heights \[cm (centimetres)\] using the Microgate system, measured at rest and after the entire exercise procedure, both before and after supplementation.

Time frame
During the first study visit on the first day and during the second study visit after 28 days of intervention.
3

Changes in aerobic capacity during incremental cycling test (ICT)

Assessment of time to exhaustion \[s (seconds)\] during an incremental cycling test (ICT) using Ergoline E100P-K, measured before and after supplementation (with BA+SB, BA+PL2, PL1+SB, or PL1+PL2).

Time frame
During the first study visit on the first day and during the second study visit after 28 days of intervention.
4

Changes in blood bicarbonate, base excess, anion gap, and lactate concentrations

Assessment of bicarbonate, base excess, anion gap, lactate \[mmol/L\] measured in capillary blood at rest, after warm-up, and after the entire exercise procedure, before and after supplementation (with BA+SB, BA+PL2, PL1+SB, or PL1+PL2).

Time frame
During the first study visit on the first day and during the second study visit after 28 days of intervention.

Secondary outcomes

1

Analysis of dietary energy intake

Assessment of energy intake \[kcal (kilocalories)\], before and after supplementation (with BA+SB, BA+PL2, PL1+SB, or PL1+PL2).

Time frame
48 h before the first study visit and the second study visit after 28 days of intervention.
2

Analysis of dietary macronutrient intake

Assessment of macronutrients intake (proteins, carbohydrates, fats) \[g (grams)\], before and after supplementation (with BA+SB, BA+PL2, PL1+SB, or PL1+PL2).

Time frame
48 h before the first study visit and the second study visit after 28 days of intervention.
3

Changes in rate of perceived exertion

The Borg RPE Scale ranges from 6 (no exertion at all) to 20 (maximal exertion). Higher scores indicate greater subjective perceived physical effort. The scale will be administered in accordance with the original methodology described by Borg (1982).

Time frame
During the first study visit on the first day and during the second study visit after 28 days of intervention.
4

Changes in heart rate

Assessment of heart rate (HR) \[bpm (beats per minute)\] during the entire exercise procedure, measured before and after supplementation (with BA+SB, BA+PL2, PL1+SB, or PL1+PL2).

Time frame
During the first study visit on the first day and during the second study visit after 28 days of intervention.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.